# Third-line Treatment of Gefitinib in NSCLC Patients

> **NCT01933347** · PHASE2 · COMPLETED · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 46 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01933347
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-07
- **Primary completion:** 2017-04-10
- **Final completion:** 2018-04-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933347, "Third-line Treatment of Gefitinib in NSCLC Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01933347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*